Ignite Creation Date:
2025-12-24 @ 11:21 PM
Ignite Modification Date:
2026-05-07 @ 4:18 AM
Study NCT ID:
NCT04323956
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-10
First Post:
2020-03-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Sponsor:
Mayo Clinic
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | View |
| None | Ann Arbor Stage II Follicular Lymphoma | View |
| None | Ann Arbor Stage II Marginal Zone Lymphoma | View |
| None | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | View |
| None | Ann Arbor Stage III Follicular Lymphoma | View |
| None | Ann Arbor Stage III Marginal Zone Lymphoma | View |
| None | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | View |
| None | Ann Arbor Stage IV Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Marginal Zone Lymphoma | View |
| None | Diffuse Large B-Cell Lymphoma | View |
| None | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 … | View |
| None | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 … | View |
| None | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | View |
| None | Indolent Non-Hodgkin Lymphoma | View |
Keywords: